Abeona Therapeutics Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Abeona Therapeutics Inc trades at $7.41 (market cap $421.19M), while Direxion Daily Semiconductor Bear 3X Shares trades at $40.73. Which is the better fit depends on your goals.
| ABEO | SOXS | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.45 | $1.49K |
52-Week Low | $4.17 | $32.50 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $39.56, down 12.5% in the past 24 hours amid a bearish technical signal. The stock split 1:10 on July 15, 2026, and paid a $0.04 dividend in June 2026. Technical indicators show oversold conditions with an RSI of 26.30, while moving averages signal a downtrend.
The outlook remains highly speculative due to SOXS's inverse leverage structure, which amplifies losses in rising markets. Risks include semiconductor sector volatility and the ETF's decay from daily rebalancing. It suits only aggressive traders betting against chip stocks, not long-term investors.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →